Summer 2015

HCS Pharma is still working during this summer. We complete our models, for exemple in oncology field with wound healing assay and 3D culture. We also have engaged a deep test of the Perkin Elmer "Operetta HCS system". Some results will be presented at the Drug Discovery meeting in Telford the 2nd and 3rd of september. We hope to see you in the innovation zone.

HCS Pharma continue de travailler durant l'été. Nous sommes en train de compléter nos modèles, par exemple en oncologie sur le développement de tests de migration ou en culture 3D. Nous avons également entamé un test en profondeur des capacités du système "Operetta" de Perkin Elmer. Nous en présenterons plusieurs résultats lors de "Drug Discovery 2015" à Telford les 2 et 3 septembre. Venez nous rencontrer dans la zone innovation !
 

Deep tests of Operetta High Content Imaging System are beginning

We just begin a test period of the Operetta “High Content Imaging System” from Perkin Elmer. First impressions are very goods, especially using confocal option for 3D imaging.

Meet us at Drug Discovery 2015 in Telford the 2nd & 3rd of September

We will be present in the “innovation zone” during the Drug discovery 2015 in Telford the 2nd and 3rd of September. The event is organised by ELRIG into 8 scientific sessions, which one is on phenotypic discovery and cell imaging.

Our feed-back of “universités d’été” organised by AFSSI in DIJON

It was really interesting to be present at the AFSSI’s “universités d’été”. About 160 business heads of CRO (contract research organisation) in biotechnology area were present.

Antoine has helped us to improve statistically our results

It was a pleasure for us to welcome Antoine at HCS Pharma for a 6 week internship focused on statistics interpretation improvement. He worked particularly on cells culture homogeneity in a 96 wells plate, and effect of cells spatial localisation in a well on results interpretation. 

“Nous devons garder notre avance dans le digital”, explique Vas Narasimhan de Novartis Pharmaceuticals

Vas Narasimhan, global head development at Novartis Pharmaceuticals, talks about the importance of digital nowadays in pharmaceutical companies. He also emphasis the need to combine different cells therapies to efficiently cure complex diseases. Of course for us, it’s also a confirmation of HCS future developments to test the efficiency of these combinations.

HCS Pharma est maintenant accrédité pour le Crédit Impôt Recherche

HCS Pharma a reçu l’agrément CIR (Crédit Impôt Recherche) du Ministère de L’Enseignement Supérieur et de la Recherche. Cette accréditation signe la reconnaissance par l’administration française de notre capacité à réaliser des travaux de recherche. Délivrée pour les 3 prochaines années, elle permet aux entreprises qui nous confient tout ou partie de leurs travaux de R&D de bénéficier du CIR au titre des prestations que nous leur facturons.

Services

Explain us your requirements and we develop your assays to best meet your needs !

Our vision

To target complex diseases (as cancer and neurodegenerative diseases), more than one target are needed and screening on complex model is recommended.

View this email in your browser
Website
Website
LinkedIn
LinkedIn
Twitter
Twitter
Google Plus
Google Plus
Contact Us
Contact Us
Copyright © 2015 HCS Pharma, All rights reserved.


unsubscribe from this list    update subscription preferences 

Email Marketing Powered by Mailchimp